FB
Therapeutic Areas
ALK Abello Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EURneffy® (neffy®) | Anaphylaxis emergency treatment | Marketed |
| Peanut Allergy Program | Peanut Allergy (Immunotherapy) | Phase 2 (assumed) |
| Next-Gen Respiratory AIT | Respiratory Allergy (Disease Modification) | Research / Pre-clinical |
| Adjacent Therapy Programs | Diseases with Type 2 Inflammation | Discovery / Research |
Leadership Team at ALK Abello
PH
Peter Halling
President & Chief Executive Officer
CS
Claus Steensen Sølje
Chief Financial Officer
EJ
Edward Jordan
EVP Commercial Operations North America
LT
Lika Thiesen
EVP Global People & Organisation
CG
Christian G. Houghton
EVP Product Supply
JG
Jacob Glenting
SVP Corporate, Portfolio & Product Strategy
JE
Jan Engel Jensen
SVP Global Quality
HM
Henriette Mersebach
Head of R&D (Stepping down per Feb 2026)